08:00 , Feb 7, 2011 |  BC Week In Review  |  Company News

Manhattan deal

Manhattan said former Ariston Pharmaceuticals Inc. shareholders will receive 8.8 million shares of Manhattan stock after the biotech said it would continue development of AST-915 to treat essential tremors. The stock is valued at $264,841,...
07:00 , Mar 22, 2010 |  BC Week In Review  |  Company News

Ariston, Manhattan Pharmaceuticals deal

Manhattan acquired Ariston in a stock deal valued at $564,800 based on Manhattan's close of $0.08 on March 11, the day before the deal was announced. Ariston shareholders received 7.1 million shares of Manhattan stock...